Related Experiment Video
Updated: Jun 13, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
When to start antiretroviral therapy.
1HIV/AIDS Division, San Francisco General Hospital, University of California-San Francisco, San Francisco, CA 94110, USA. vivek.jain@ucsf.edu
Current HIV/AIDS Reports
|April 29, 2010
Summary
Starting combination antiretroviral therapy earlier for HIV may offer significant benefits. Early treatment can prevent serious illness, immune system damage, and transmission, potentially outweighing medication risks for motivated patients.
Area of Science:
- Infectious Diseases
- Immunology
- Public Health
Background:
- The optimal timing for initiating combination antiretroviral therapy (cART) in treatment-naïve HIV patients remains a subject of debate.
- Current major guidelines present divergent recommendations for cART initiation strategies.
- A discernible trend towards earlier cART initiation has emerged despite the lack of definitive consensus.
Purpose of the Study:
- To explore the rationale and implications of the recent shift towards earlier initiation of cART in HIV management.
- To evaluate the potential benefits of early cART, including prevention of non-AIDS-related complications and immune preservation.
- To assess the public health impact of early cART, specifically its role in preventing HIV transmission.
Main Methods:
- This analysis is based on a review of current clinical observations and guideline recommendations regarding HIV treatment initiation.
- The study synthesizes evidence supporting the benefits of early viral suppression through cART.
- Consideration of patient motivation and willingness to adhere to early treatment regimens is discussed.
Main Results:
- Effective viral suppression via cART is associated with reduced non-AIDS-related morbidity and mortality.
- Early cART initiation can mitigate irreversible damage to the human immune system.
- Therapeutic intervention may significantly reduce HIV transmission rates, offering a public health advantage.
Conclusions:
- For motivated individuals, the advantages of early HIV therapy, including improved health outcomes and reduced transmission, may supersede the known risks of antiretroviral drugs.
- The decision to initiate cART should be individualized, weighing potential benefits against medication-related risks.
- Earlier cART initiation represents a paradigm shift in HIV management, emphasizing both individual and public health benefits.
More Related Videos
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
02:33Retroviruses
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:26Sexually Transmitted Infections
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...